Boehringer Ingelheim. (12/19/22). "Press Release: Boehringer Ingelheim and Click Therapeutics Expand Their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia". Ingelheim & New York, NY.

	Organisation	Boehringer Ingelheim (Group)
	Organisation 2	Click Therapeutics Inc.
	Product	CT-155 digital therapeutic
	Index term	Boehringer–Click Therapeutics: digital therapeutics, 202212– collab expansion to develop 2nd DTx for schizophrenia up to $460m + royalties
	Person	Pipic, Nedim (Boehringer 202212 Corporate VP, Therapeutic Area Head CNS, Retinopathies + Emerging Areas)
	Person 2	Klein, David Benshoof (Click Therapeutics 202009 CEO)

Boehringer Ingelheim and Click Therapeutics today announced the launch of an expanded collaboration for the development and commercialization of a second prescription-based digital therapeutic (PDT). The companies will collaborate to develop and commercialize a novel mobile application, which combines multiple clinically validated therapeutic interventions for use alone and in combination with pharmaceutical therapy to help people with schizophrenia achieve positive clinical outcomes. The partnership aims to provide additional treatment options to those living with schizophrenia, where there remains a significant unmet need due to lack of access to psychosocial intervention therapies.

Schizophrenia is one of the 15 leading causes of disability worldwide, with approximately half of all patients exhibiting co-occurring mental and/or behavioral health disorders.1 It is a serious mental health condition that alters a person’s perception of reality and impacts how they think, feel, and behave, and people diagnosed with schizophrenia can remain functionally impaired due to insufficiently treated negative symptoms, including cognitive deficits and limited social functioning.2 Treatment guidelines recommend tailored psychosocial intervention therapies, however, access to these interventions is limited. 2,3 Providing novel, digital therapeutic options has the potential to significantly improve treatment and positively impact health and patient’s quality of life.

The additional prescription digital therapeutic under this expanded collaboration builds on development and clinical successes together with key patient insights gained under the companies’ existing collaboration, which has been in effect since September 2020. The CT-155 program has achieved all development milestones to-date and generated supportive data across clinical learning studies in advance of an upcoming pivotal registration study. The companies are pursuing this new therapy after recognizing that a comprehensive treatment strategy for schizophrenia would benefit from a multi-product approach. Click Therapeutics will receive an upfront payment, funding for research and development activities as well as clinical, regulatory and commercial milestone payments up to a total of USD 460 million, plus tiered royalties.

“We are very excited to expand our collaboration with Click Therapeutics and further tap into their expertise in developing efficacious and engaging digital therapeutics. This brings us an important step closer to our aim of developing holistic mental health solutions for patients in need. It opens new horizons on our journey toward advancing mental healthcare by combining pharmacotherapies with newly emerging digital technologies,” said Nedim Pipic, MD, Corporate Vice President, Therapeutic Area Head CNS, Retinopathies & Emerging Areas, Boehringer Ingelheim.

“Our collaboration with Boehringer Ingelheim offers significant potential to bring new digital treatment options to a currently underserved patient population,” said David Benshoof Klein, CEO, Click Therapeutics. “Our teams share a passion to pursue new, groundbreaking approaches to treatment and a mission to make a difference for patients. We are thrilled to expand our relationship with Boehringer Ingelheim to additional treatments within schizophrenia.”

“With this new project we are addressing symptoms of patients for which no scalable treatment approaches exist today. Seeing the pipeline of PDTs growing reflects our commitment to mental health. We are excited to realize the potential of complementing pharmacological therapy with digital solutions to transform the lives of patients,” added Cornelia Dorner-Ciossek, Ph.D., Digital Health Lead at Boehringer Ingelheim.

“Expanding our successful partnership with Boehringer Ingelheim enables our team to build on the experience and insights gathered with CT-155 and further expand the scope of our digital therapeutics platform,” said Austin Speier, Chief Strategy Officer, Click Therapeutics. “This growing collaboration is a testament to the progress we have achieved so far working together and creates the inspiring opportunity to expand CT-155 into a seamless digital therapy suite that can deliver meaningful outcomes to people living with schizophrenia.”

About Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com.

About Click Therapeutics

Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for patients with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program has entered a pivotal, fully remote, randomized, controlled trial on the Verily platform for the treatment of Major Depressive Disorder (MDD) in up to 360 adults. Click is progressing a broad pipeline of Digital Therapeutics™ across a variety of high-burden therapeutic areas, including MDD, Schizophrenia, Migraine, MS, Chronic Pain, Atopic Dermatitis, Acute Coronary Syndrome (ACS), Obesity, Oncology and more. For more information on Click, visit www.ClickTherapeutics.com.

References

1. National Institute of Mental Health. (May 2018). Schizophrenia Statistics [Website]. https://www.nimh.nih.gov/health/statistics/schizophrenia.shtml#part_154881 Accessed July 20, 2020.

2. National Institute of Mental Health. (May 2020). Schizophrenia [Website]. https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml Accessed July 20, 2020.

3. Kozloff, N., Mulsant, B. H., Stergiopoulos, V., & Voineskos, A. N. (2020). The COVID-19 Global Pandemic: Implications for People With Schizophrenia and Related Disorders. Schizophrenia bulletin, 46(4), 752–757. https://doi.org/10.1093/schbul/sbaa051

Media Contacts

Boehringer Ingelheim

Reinhard Malin (CET time zone)
Innovation Unit/Bio Comms, Corp. Affairs
P: 49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com

Linda Ruckel (ET time zone)
Innovation Unit/Bio Comms, Corp. Affairs
P: 1 203-791-6672
linda.ruckel@boehringer-ingelheim.com

Click Therapeutics

Daniel Busby (Investor Contact)
dbusby@clicktherapeutics.com

Jonni Mills (Media Contact)
jmills@clicktherapeutics.com

Record changed: 2024-01-06